Literature DB >> 16512982

Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer.

Eric B Haura1, Sandy Livingston, Domenico Coppola.   

Abstract

Autocrine growth factor stimulation resulting in growth self-sufficiency is a hallmark of cancer. Classically, non-small-cell lung cancer (NSCLC) cells have autocrine epidermal growth factor stimulation through coexpression of receptors and ligands. In addition to epidermal growth factor receptor and other growth factor ligand-receptor autocrine loops, increasing evidence suggests important roles for cytokines in mediating intracellular signaling events important in cell growth and survival. Interleukin-6 (IL-6) has been shown to activate pathways important in tumorigenesis including Janus kinase/signal transducer and activator of transcription, phosphotidylinositol 3-kinase/Akt, and extracellular signal-regulated kinase signaling. Using immunohistochemistry, we demonstrate that NSCLC specimens have tumor expression of IL-6 and IL-6 receptor components gp80 and gp130. These results suggest that IL-6 autocrine signaling might contribute to downstream signaling events in NSCLC and further support the concept of multiple autocrine pathways contributing to the pathogenesis of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16512982     DOI: 10.3816/CLC.2006.n.006

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  30 in total

1.  An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Authors:  Owen W Stephens; Qing Zhang; Pingping Qu; Yiming Zhou; Shweta Chavan; Erming Tian; David R Williams; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer.

Authors:  Joong-Jae Lee; Hyun Jung Kim; Chul-Su Yang; Hyun-Ho Kyeong; Jung-Min Choi; Da-Eun Hwang; Jae-Min Yuk; Keunwan Park; Yu Jung Kim; Seung-Goo Lee; Dongsup Kim; Eun-Kyeong Jo; Hae-Kap Cheong; Hak-Sung Kim
Journal:  Mol Ther       Date:  2014-03-31       Impact factor: 11.454

3.  Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer.

Authors:  Yuping D Li; Jonathan B Lamano; Jason B Lamano; Jessica Quaggin-Smith; Dorina Veliceasa; Gurvinder Kaur; Dauren Biyashev; Dusten Unruh; Orin Bloch
Journal:  Cancer Immunol Immunother       Date:  2019-09-05       Impact factor: 6.968

4.  Sex Hormones and Lung Inflammation.

Authors:  Jorge Reyes-García; Luis M Montaño; Abril Carbajal-García; Yong-Xiao Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  TGF-β/SMAD3 Pathway Stimulates Sphingosine-1 Phosphate Receptor 3 Expression: IMPLICATION OF SPHINGOSINE-1 PHOSPHATE RECEPTOR 3 IN LUNG ADENOCARCINOMA PROGRESSION.

Authors:  Jiawei Zhao; Jingjing Liu; Jen-Fu Lee; Wenliang Zhang; Mustapha Kandouz; Garrett C VanHecke; Shiyou Chen; Young-Hoon Ahn; Fulvio Lonardo; Menq-Jer Lee
Journal:  J Biol Chem       Date:  2016-11-17       Impact factor: 5.157

6.  Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.

Authors:  Laura P Stabile; Mariya Farooqui; Beatriz Kanterewicz; Shira Abberbock; Brenda F Kurland; Brenda Diergaarde; Jill M Siegfried
Journal:  J Thorac Oncol       Date:  2017-12-09       Impact factor: 15.609

7.  EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.

Authors:  Timothy D Clay; Prudence A Russell; Hongdo Do; Vijaya Sundararajan; Matthew Conron; Gavin M Wright; Benjamin Solomon; Alexander Dobrovic; Sue-Anne McLachlan; Melissa M Moore
Journal:  Med Oncol       Date:  2017-09-06       Impact factor: 3.064

8.  Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.

Authors:  Lanxi Song; Matthew A Smith; Parul Doshi; Kate Sasser; William Fulp; Soner Altiok; Eric B Haura
Journal:  J Thorac Oncol       Date:  2014-07       Impact factor: 15.609

9.  Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells.

Authors:  Na-Hyun Kim; Seong-Kwan Kim; Dong-Soon Kim; Dan Zhang; Jin-A Park; Hee Yi; Jin-Suk Kim; Ho-Chul Shin
Journal:  Oncol Lett       Date:  2015-03-09       Impact factor: 2.967

10.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.

Authors:  Sizhi Paul Gao; Kevin G Mark; Kenneth Leslie; William Pao; Noriko Motoi; William L Gerald; William D Travis; William Bornmann; Darren Veach; Bayard Clarkson; Jacqueline F Bromberg
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.